Choose Your Country or Region

S6 Kinase

Isoform-selective Products

p70 S6K p70 S6K1 RSK1 RSK2 RSK3 RSK4

Signaling Pathway

S6 Kinase Products

All (29)
S6 Kinase Inhibitors (19)
New S6 Kinase Products

Catalog No.	Product Name	Information	Product Use Citations
S1582	H 89 2HCl	H 89 2HCl is a potent PKA inhibitor with K_i of 48 nM in a cell-free assay, 10-fold selective for PKA than PKG,500-fold greater selectivity than PKC, MLCK, calmodulin kinase II and casein kinase I/II. H 89 2HCl induces autophagy.	J Cachexia Sarcopenia Muscle, 2025, 16(3):e13853 Commun Biol, 2025, 8(1):178 iScience, 2025, 28(2):111833
S1421	Staurosporine (STS)	Staurosporine (STS) is a potent PKC inhibitor for PKCα, PKCγ and PKCη with IC50 of 2 nM, 5 nM and 4 nM, less potent to PKCδ (20 nM), PKCε (73 nM) and little active to PKCζ (1086 nM) in cell-free assays. Also shows inhibitory activities on other kinases, such as PKA, PKG, S6K, CaMKII, etc. Phase 3.	Cell Metab, 2025, S1550-4131(25)00149-4 Cell Death Dis, 2025, 16(1):396 Genes Dis, 2025, 12(3):101321
S1014	Bosutinib	Bosutinib is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively. Bosutinib also effectively decreases the activity of PI3K/AKT/mTOR, MAPK/ERK and JAK/STAT3 signaling pathways by blocking the phosphorylation levels of p-ERK, p-S6, and p-STAT3. Bosutinib promotes autophagy.	Blood Adv, 2025, bloodadvances.2024015364 Virulence, 2025, 16(1):2489751 Elife, 2024, 12RP92324
S2843	BI-D1870	BI-D1870 is an ATP-competitive inhibitor of S6 ribosome for RSK1/2/3/4 with IC50 of 31 nM/24 nM/18 nM/15 nM in cell-free assays, respectively; 10- to 100-fold selectivity for RSK than MST2, GSK-3β, MARK3, CK1 and Aurora B. BI-D1870 exhibits anticancer attributes including the generation of reactive oxygen species (ROS) and increases in endoplasmic reticulum (ER) stress and autophagy.	Cells, 2024, 13(18)1546 Sci Rep, 2024, 14(1):9440 BMC Cancer, 2024, 24(1):233
S2163	PF-4708671	PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with K_i/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. PF-4708671 induces autophagy. First S6K1-specific inhibitor to be reported.	Mediators Inflamm, 2025, 2025:8108993 Nat Cell Biol, 2024, 10.1038/s41556-024-01473-0 Int J Mol Sci, 2024, 25(7)3944
S1558	AT7867	AT7867 is a potent ATP-competitive inhibitor of Akt1/2/3 and p70S6K/PKA with IC50 of 32 nM/17 nM/47 nM and 85 nM/20 nM in cell-free assays, respectively; little activity outside the AGC kinase family.	Exp Gerontol, 2023, 173:112091 Cancers (Basel), 2022, 14(21)5215 Oncoimmunology, 2021, 10(1):1943234
S7698	LY2584702	LY2584702 is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM.	Sci Adv, 2025, 11(29):eadv1492 Mol Cell, 2024, S1097-2765(24)00832-3 J Exp Clin Cancer Res, 2024, 43(1):321
S7704	LY2584702 Tosylate	LY2584702 Tosylate is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.	Blood Adv, 2024, 8(15):3880-3892 Cell, 2023, 186(24):5328-5346.e26 Cell, 2023, 10.1016/j.cell.2023.09.027
S7563	AT13148	AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.	Neoplasia, 2023, 10.1016/j.neo.2023.100948 Cancers (Basel), 2022, 14(23)5943 Br J Cancer, 2021, 10.1038/s41416-021-01442-6
S6385	Prexasertib (LY2606368)	Prexasertib (LY2606368, ACR 368) is a selective ATP competitor inhibitor of Chk1 and Chk2 with IC50s of 1 nM and 8 nM in cell-free assays, respectively. Prexasertib also inhibits RSK1 with an IC50 of 9 nM in cell-free assay.	Cell Rep Med, 2025, S2666-3791(25)00151-X Mol Oncol, 2025, 19(6):1633-1650 Biomol Ther (Seoul), 2025, 33(3):458-469
S8518	AD80	AD80, a multikinase inhibitor, shows strong activity against human RET (c-RET), BRAF, S6K, and SRC but were much less active than either AD57 or AD58 against mTOR. The IC50 value for RET is 4 nM.	Nat Commun, 2022, 13(1):2500 Mol Cancer Res, 2020, 18(8):1176-1188 Mol Cancer Res, 2020, 1176-1188
S7871	LJI308	LJI308 is a potent, and pan-RSK (p90 ribosomal S6 kinase) inhibitor with IC50 of 6 nM, 4 nM, and 13 nM for RSK1, RSK2, and RSK3, respectively.	Nat Commun, 2024, 15(1):2089 J Exp Clin Cancer Res, 2022, 41-1:256 Cell Rep, 2022, 41(11):111827
S7870	LJH685	LJH685 is a potent pan-RSK inhibitor with IC50 of 6 nM, 5 nM and 4 nM for RSK1, RSK2, and RSK3, respectively.	Biol Pharm Bull, 2025, 48(2):172-176 Cell Rep, 2022, 38(11):110522 Front Mol Biosci, 2022, 9:1030725
S7752	Pluripotin (SC1)	Pluripotin (SC1) is a dual inhibitor of extracellular signal-regulated kinase 1 (ERK1, MAPK3) and RasGAP. Maintains embryonic stem cell (ESC) self-renewal. Pluripotin also inhibits RSK1, RSK2, RSK3 and RSK4 with IC50 of 0.5 µM, 2.5 µM, 3.3 µM and 10.0 µM, respectively.	J Clin Biochem Nutr, 2024, 74(2):97-107 Antiviral Res, 2018, 157:57-67 Reprod Domest Anim, 2018, 53(5):1052-1059
F0011	Anti-p70 S6 Kinase Rabbit Antibody [D7E4]	p70 S6 Kinase,p70 S6 kinase α,p70 S6 kinase/S6K1,S6K1
F0198^New	Anti-Phospho-S6 Ribosomal Protein (S235/236) Rabbit Antibody [G7G11]	Phospho-S6 Ribosomal Protein (Ser235/236),RPS6 (phospho S235 + S236)
F0163^New	Anti-S6 Ribosomal Protein Rabbit Antibody [H23F3]	Ribosomal Protein S6,RPS6,S6 Ribosomal Protein
F0503^New	Anti-Phospho-p90RSK (Ser380) Rabbit Antibody [F5E5]	Ribosomal protein S6 kinase alpha-3, S6K-alpha-3, S6K-α-3, 90 kDa ribosomal protein S6 kinase 3, p90-RSK 3, p90RSK3, Insulin-stimulated protein kinase 1 , ISPK-1, MAP kinase-activated protein kinase 1b, MAPK-activated protein kinase 1b, MAPKAP kinase 1b, MAPKAPK-1b, Ribosomal S6 kinase 2, RSK-2, p90RSK2, RPS6KA3, ISPK1, MAPKAPK1B, RSK2, Ribosomal protein S6 kinase alpha-2, S6K-alpha-2, S6K-α-2, 90 kDa ribosomal protein S6 kinase 2, p90-RSK 2, p90RSK2, MAP kinase-activated protein kinase 1c, MAPK-activated protein kinase 1c, MAPKAP kinase 1c, MAPKAPK-1c, Ribosomal S6 kinase 3, RSK-3, RPS6KA2, MAPKAPK1C, RSK3, S6K-alpha-1, p90-RSK 1, p90RSK1, p90S6K, MAPKAP kinase 1a, MAPKAPK-1a, RSK-1, RPS6KA1, MAPKAPK1A, RSK1, Ribosomal S6 kinase 1
F2933^New	Anti-P70 S6 Kinase beta/SRK-N-terminal Rabbit Antibody [G11B4]	p70 S6 Kinase 2,P70 S6 Kinase beta/SRK,Phospho-(Ser/Thr) PKA Substrate,RPS6KB2
F0506^New	Anti-RSK1/RSK2/RSK3 Rabbit Antibody [N15F10]	S6K-alpha-3, S6K-α-3, p90-RSK 3; p90RSK3, ISPK-1, MAPKAP kinase 1b, MAPKAPK-1b, RSK-2, p90RSK2, RPS6KA3, ISPK1, MAPKAPK1B, RSK2, S6K-alpha-2, S6K-α-2, p90-RSK 2, p90RSK2, MAPKAP kinase 1c, MAPKAPK-1c, RSK-3, RPS6KA2, MAPKAPK1C, RSK3, S6K-alpha-1, p90-RSK 1, p90RSK1, p90S6K, MAPKAP kinase 1a, MAPKAPK-1a, RSK-1, RPS6KA1, MAPKAPK1A, RSK1
F0557^New	Anti-Phospho-p90 RSK (Thr359) Rabbit Antibody [M10J19]	Phospho-p90RSK (Thr359),RSK1 p90 (phospho T359)
S3940	3'-Hydroxypterostilbene	3'-Hydroxypterostilbene (3'-HPT) is one of the active constituents of Sphaerophysa salsula and Pterocarpus marsupium which may be useful in treating different types of haematological malignancies. 3'-Hydroxypterostilbene, a natural pterostilbene analogue, effectively inhibits the growth of human colon cancer cells (IC50s of 9.0, 40.2, and 70.9 µM for COLO 205, HCT-116, and HT-29 cells, respectively) by inducing apoptosis and autophagy. 3'-Hydroxypterostilbene inhibits the PI3K/Akt/mTOR/p70S6K, and p38MAPK pathways and activates the ERK1/2, JNK1/2 MAPK pathways.	Int J Mol Sci, 2024, 25(18)9990
F0904	Anti-Phospho-RSK2 (Ser227) Rabbit Antibody [F3D15]	S6K-alpha-3, S6K-α-3, p90-RSK 3; p90RSK3, ISPK-1, MAPKAP kinase 1b, MAPKAPK-1b, RSK-2, p90RSK2, RPS6KA3, ISPK1, MAPKAPK1B, RSK2
E1754	BRD7389	BRD7389 is an inhibitor of RSK family kinases with IC50 of 1.5 μM, 2.4 μM, and 1.2 μM for RSK1, RSK2, and RSK3, respectively. BRD7389 also increases β-cell–specific gene expression in primary human islet cells.
S0385	S6K-18	S6K-18 is a highly selective inhibitor of ribosomal protein S6 kinase beta-1 (S6K1, p70S6K, p70-S6K).	Elife, 2024, 13RP92925 Item – Theses Canada, 2016,
F0812^New	Anti-RSK2 Rabbit Antibody [B14G11]	RSK2,Rsk-2
E4345	L-Norvaline	L-Norvaline is a non-proteinogenic amino acid, an isomer of valine, and an inhibitor of arginase and p70 ribosomal S6 kinase 1 (p70S6K1) kinase. L-norvaline enhances NO production from activated macrophages.
E4690^New	Gingerenone A	Gingerenone A is a a polyphenol present in ginger, an inhibitor of p70 S6 (S6K1) and an activator of Nrf2-Gpx4 signaling pathway to alleviate ferroptosis in secondary liver injury in colitis. It exhibits anti-adipogenic, anti-lipogenic, anti-hyperglycemic, anti-obesity, and anti-inflammatory effects, and holds promise for research into anti-diabetic and anti-obesity drug development.
F0303^New	Anti-Phospho-S6 Ribosomal Protein (Ser240/244) Rabbit Antibody [H21K17]	Phospho-S6 Ribosomal Protein (Ser240/244),RPS6 (phospho S240 + S244)
S1582	H 89 2HCl	H 89 2HCl is a potent PKA inhibitor with K_i of 48 nM in a cell-free assay, 10-fold selective for PKA than PKG,500-fold greater selectivity than PKC, MLCK, calmodulin kinase II and casein kinase I/II. H 89 2HCl induces autophagy.	J Cachexia Sarcopenia Muscle, 2025, 16(3):e13853 Commun Biol, 2025, 8(1):178 iScience, 2025, 28(2):111833
S1421	Staurosporine (STS)	Staurosporine (STS) is a potent PKC inhibitor for PKCα, PKCγ and PKCη with IC50 of 2 nM, 5 nM and 4 nM, less potent to PKCδ (20 nM), PKCε (73 nM) and little active to PKCζ (1086 nM) in cell-free assays. Also shows inhibitory activities on other kinases, such as PKA, PKG, S6K, CaMKII, etc. Phase 3.	Cell Metab, 2025, S1550-4131(25)00149-4 Cell Death Dis, 2025, 16(1):396 Genes Dis, 2025, 12(3):101321
S1014	Bosutinib	Bosutinib is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively. Bosutinib also effectively decreases the activity of PI3K/AKT/mTOR, MAPK/ERK and JAK/STAT3 signaling pathways by blocking the phosphorylation levels of p-ERK, p-S6, and p-STAT3. Bosutinib promotes autophagy.	Blood Adv, 2025, bloodadvances.2024015364 Virulence, 2025, 16(1):2489751 Elife, 2024, 12RP92324
S2843	BI-D1870	BI-D1870 is an ATP-competitive inhibitor of S6 ribosome for RSK1/2/3/4 with IC50 of 31 nM/24 nM/18 nM/15 nM in cell-free assays, respectively; 10- to 100-fold selectivity for RSK than MST2, GSK-3β, MARK3, CK1 and Aurora B. BI-D1870 exhibits anticancer attributes including the generation of reactive oxygen species (ROS) and increases in endoplasmic reticulum (ER) stress and autophagy.	Cells, 2024, 13(18)1546 Sci Rep, 2024, 14(1):9440 BMC Cancer, 2024, 24(1):233
S2163	PF-4708671	PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with K_i/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. PF-4708671 induces autophagy. First S6K1-specific inhibitor to be reported.	Mediators Inflamm, 2025, 2025:8108993 Nat Cell Biol, 2024, 10.1038/s41556-024-01473-0 Int J Mol Sci, 2024, 25(7)3944
S1558	AT7867	AT7867 is a potent ATP-competitive inhibitor of Akt1/2/3 and p70S6K/PKA with IC50 of 32 nM/17 nM/47 nM and 85 nM/20 nM in cell-free assays, respectively; little activity outside the AGC kinase family.	Exp Gerontol, 2023, 173:112091 Cancers (Basel), 2022, 14(21)5215 Oncoimmunology, 2021, 10(1):1943234
S7698	LY2584702	LY2584702 is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM.	Sci Adv, 2025, 11(29):eadv1492 Mol Cell, 2024, S1097-2765(24)00832-3 J Exp Clin Cancer Res, 2024, 43(1):321
S7704	LY2584702 Tosylate	LY2584702 Tosylate is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.	Blood Adv, 2024, 8(15):3880-3892 Cell, 2023, 186(24):5328-5346.e26 Cell, 2023, 10.1016/j.cell.2023.09.027
S7563	AT13148	AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.	Neoplasia, 2023, 10.1016/j.neo.2023.100948 Cancers (Basel), 2022, 14(23)5943 Br J Cancer, 2021, 10.1038/s41416-021-01442-6
S6385	Prexasertib (LY2606368)	Prexasertib (LY2606368, ACR 368) is a selective ATP competitor inhibitor of Chk1 and Chk2 with IC50s of 1 nM and 8 nM in cell-free assays, respectively. Prexasertib also inhibits RSK1 with an IC50 of 9 nM in cell-free assay.	Cell Rep Med, 2025, S2666-3791(25)00151-X Mol Oncol, 2025, 19(6):1633-1650 Biomol Ther (Seoul), 2025, 33(3):458-469
S8518	AD80	AD80, a multikinase inhibitor, shows strong activity against human RET (c-RET), BRAF, S6K, and SRC but were much less active than either AD57 or AD58 against mTOR. The IC50 value for RET is 4 nM.	Nat Commun, 2022, 13(1):2500 Mol Cancer Res, 2020, 18(8):1176-1188 Mol Cancer Res, 2020, 1176-1188
S7871	LJI308	LJI308 is a potent, and pan-RSK (p90 ribosomal S6 kinase) inhibitor with IC50 of 6 nM, 4 nM, and 13 nM for RSK1, RSK2, and RSK3, respectively.	Nat Commun, 2024, 15(1):2089 J Exp Clin Cancer Res, 2022, 41-1:256 Cell Rep, 2022, 41(11):111827
S7870	LJH685	LJH685 is a potent pan-RSK inhibitor with IC50 of 6 nM, 5 nM and 4 nM for RSK1, RSK2, and RSK3, respectively.	Biol Pharm Bull, 2025, 48(2):172-176 Cell Rep, 2022, 38(11):110522 Front Mol Biosci, 2022, 9:1030725
S7752	Pluripotin (SC1)	Pluripotin (SC1) is a dual inhibitor of extracellular signal-regulated kinase 1 (ERK1, MAPK3) and RasGAP. Maintains embryonic stem cell (ESC) self-renewal. Pluripotin also inhibits RSK1, RSK2, RSK3 and RSK4 with IC50 of 0.5 µM, 2.5 µM, 3.3 µM and 10.0 µM, respectively.	J Clin Biochem Nutr, 2024, 74(2):97-107 Antiviral Res, 2018, 157:57-67 Reprod Domest Anim, 2018, 53(5):1052-1059
S3940	3'-Hydroxypterostilbene	3'-Hydroxypterostilbene (3'-HPT) is one of the active constituents of Sphaerophysa salsula and Pterocarpus marsupium which may be useful in treating different types of haematological malignancies. 3'-Hydroxypterostilbene, a natural pterostilbene analogue, effectively inhibits the growth of human colon cancer cells (IC50s of 9.0, 40.2, and 70.9 µM for COLO 205, HCT-116, and HT-29 cells, respectively) by inducing apoptosis and autophagy. 3'-Hydroxypterostilbene inhibits the PI3K/Akt/mTOR/p70S6K, and p38MAPK pathways and activates the ERK1/2, JNK1/2 MAPK pathways.	Int J Mol Sci, 2024, 25(18)9990
E1754	BRD7389	BRD7389 is an inhibitor of RSK family kinases with IC50 of 1.5 μM, 2.4 μM, and 1.2 μM for RSK1, RSK2, and RSK3, respectively. BRD7389 also increases β-cell–specific gene expression in primary human islet cells.
S0385	S6K-18	S6K-18 is a highly selective inhibitor of ribosomal protein S6 kinase beta-1 (S6K1, p70S6K, p70-S6K).	Elife, 2024, 13RP92925 Item – Theses Canada, 2016,
E4345	L-Norvaline	L-Norvaline is a non-proteinogenic amino acid, an isomer of valine, and an inhibitor of arginase and p70 ribosomal S6 kinase 1 (p70S6K1) kinase. L-norvaline enhances NO production from activated macrophages.
E4690^New	Gingerenone A	Gingerenone A is a a polyphenol present in ginger, an inhibitor of p70 S6 (S6K1) and an activator of Nrf2-Gpx4 signaling pathway to alleviate ferroptosis in secondary liver injury in colitis. It exhibits anti-adipogenic, anti-lipogenic, anti-hyperglycemic, anti-obesity, and anti-inflammatory effects, and holds promise for research into anti-diabetic and anti-obesity drug development.
F0198^New	Anti-Phospho-S6 Ribosomal Protein (S235/236) Rabbit Antibody [G7G11]	Phospho-S6 Ribosomal Protein (Ser235/236),RPS6 (phospho S235 + S236)
F0163^New	Anti-S6 Ribosomal Protein Rabbit Antibody [H23F3]	Ribosomal Protein S6,RPS6,S6 Ribosomal Protein
F0503^New	Anti-Phospho-p90RSK (Ser380) Rabbit Antibody [F5E5]	Ribosomal protein S6 kinase alpha-3, S6K-alpha-3, S6K-α-3, 90 kDa ribosomal protein S6 kinase 3, p90-RSK 3, p90RSK3, Insulin-stimulated protein kinase 1 , ISPK-1, MAP kinase-activated protein kinase 1b, MAPK-activated protein kinase 1b, MAPKAP kinase 1b, MAPKAPK-1b, Ribosomal S6 kinase 2, RSK-2, p90RSK2, RPS6KA3, ISPK1, MAPKAPK1B, RSK2, Ribosomal protein S6 kinase alpha-2, S6K-alpha-2, S6K-α-2, 90 kDa ribosomal protein S6 kinase 2, p90-RSK 2, p90RSK2, MAP kinase-activated protein kinase 1c, MAPK-activated protein kinase 1c, MAPKAP kinase 1c, MAPKAPK-1c, Ribosomal S6 kinase 3, RSK-3, RPS6KA2, MAPKAPK1C, RSK3, S6K-alpha-1, p90-RSK 1, p90RSK1, p90S6K, MAPKAP kinase 1a, MAPKAPK-1a, RSK-1, RPS6KA1, MAPKAPK1A, RSK1, Ribosomal S6 kinase 1
F2933^New	Anti-P70 S6 Kinase beta/SRK-N-terminal Rabbit Antibody [G11B4]	p70 S6 Kinase 2,P70 S6 Kinase beta/SRK,Phospho-(Ser/Thr) PKA Substrate,RPS6KB2
F0506^New	Anti-RSK1/RSK2/RSK3 Rabbit Antibody [N15F10]	S6K-alpha-3, S6K-α-3, p90-RSK 3; p90RSK3, ISPK-1, MAPKAP kinase 1b, MAPKAPK-1b, RSK-2, p90RSK2, RPS6KA3, ISPK1, MAPKAPK1B, RSK2, S6K-alpha-2, S6K-α-2, p90-RSK 2, p90RSK2, MAPKAP kinase 1c, MAPKAPK-1c, RSK-3, RPS6KA2, MAPKAPK1C, RSK3, S6K-alpha-1, p90-RSK 1, p90RSK1, p90S6K, MAPKAP kinase 1a, MAPKAPK-1a, RSK-1, RPS6KA1, MAPKAPK1A, RSK1
F0557^New	Anti-Phospho-p90 RSK (Thr359) Rabbit Antibody [M10J19]	Phospho-p90RSK (Thr359),RSK1 p90 (phospho T359)
F0812^New	Anti-RSK2 Rabbit Antibody [B14G11]	RSK2,Rsk-2
E4690^New	Gingerenone A	Gingerenone A is a a polyphenol present in ginger, an inhibitor of p70 S6 (S6K1) and an activator of Nrf2-Gpx4 signaling pathway to alleviate ferroptosis in secondary liver injury in colitis. It exhibits anti-adipogenic, anti-lipogenic, anti-hyperglycemic, anti-obesity, and anti-inflammatory effects, and holds promise for research into anti-diabetic and anti-obesity drug development.
F0303^New	Anti-Phospho-S6 Ribosomal Protein (Ser240/244) Rabbit Antibody [H21K17]	Phospho-S6 Ribosomal Protein (Ser240/244),RPS6 (phospho S240 + S244)

Choose Selective S6 Kinase Inhibitors